Pradaxa Almost Clear Of NICE Hurdle
This article was originally published in The Pink Sheet Daily
Executive Summary
Boehringer Ingelheim has answered all of NICE's questions on Pradaxa, meaning it is on the brink of being used in the NHS.
You may also be interested in...
NICE Clears Pradaxa For Stroke Prevention, Rejects Appeal By NHS Budget Holders
Following a failed appeal by regional NHS payers worried about its cost, Boehringer Ingelheim's Pradaxa is finally recommended by the U.K.'s cost watchdog, NICE, for preventing stroke associated with atrial fibrillation.
Xarelto And Pradaxa Stumble At High U.K. Reimbursement Hurdles
NICE issues draft rejection of Bayer's blood thinner Xarelto for use in preventing stroke associated with atrial fibrillation, while a U.K. payer fights a positive recommendation for Boehringer Ingelheim's Pradaxa in the same indication.
Xarelto's Efficacy Impresses In ACS, But Bleeding Risk Will Complicate Approval
Bayer/Johnson & Johnson's rivaroxaban demonstrated a significant reduction in the risk of major adverse cardiovascular events, but it also significantly increased the risk of major bleeding in the Phase III ATLAS trial of acute coronary syndrome patients.